Literature DB >> 3138241

Heterotopic ossification as a complication of acetabular fracture. Prophylaxis with low-dose irradiation.

M J Bosse1, A Poka, C M Reinert, F Ellwanger, R Slawson, E R McDevitt.   

Abstract

In a retrospective review of thirty-seven patients who had operative treatment for thirty-eight complex acetabular fractures, postoperative low-dose irradiation was administered to seventeen patients (eighteen fractures) to suppress heterotopic ossification. All of the patients had been operated on through either an extended iliofemoral incision or a modified extended iliofemoral incision. The prophylactic radiation was administered using a low-dose protocol; most of the patients received 1,000 rads in 200-rad increments, starting on the third post-operative day. The incidence of heterotopic ossification in the eighteen irradiated limbs was much lower than in the twenty patients who comprised the control group (50 per cent compared with 90 per cent). Only two of the irradiated limbs had Class-3 heterotopic ossification as described by Brooker et al., and no patient had Class-4 (ankylosis of the hip). Of the twenty control-group patients, ten had severe heterotopic ossification: Class 3 in seven and Class 4 in three. The difference in the incidence of severe (Class-3 or 4) heterotopic ossification between the two groups of patients was significant (p less than 0.01).

Entities:  

Mesh:

Year:  1988        PMID: 3138241

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  13 in total

1.  Heterotopic ossification post navigated high tibial osteotomy.

Authors:  Mustafa Citak; Daniel Kendoff; Padhraig F O'Loughlin; Andrew D Pearle
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-11-26       Impact factor: 4.342

2.  Supra-acetabular osteotomy in a 3-week-old acetabular fracture.

Authors:  H Nooraie; F Jaberi; H Droodchi
Journal:  Arch Orthop Trauma Surg       Date:  1994       Impact factor: 3.067

Review 3.  [Value of a combined ossification prophylaxis with indomethacin and radiotherapy for acetabular fractures].

Authors:  S Piatek; T Westphal; D Arbter; S Winckler
Journal:  Unfallchirurg       Date:  2006-07       Impact factor: 1.000

4.  Surgically treated acetabular fractures in adult patients.

Authors:  H Nooraie; A Ensafdaran; M M Arasteh; H Droodchi
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

5.  Does Postoperative Radiation Decrease Heterotopic Ossification After the Kocher-Langenbeck Approach for Acetabular Fracture?

Authors:  Jason A Davis; Brennan Roper; John W Munz; Timothy S Achor; Matthew Galpin; Andrew M Choo; Joshua L Gary
Journal:  Clin Orthop Relat Res       Date:  2016-06       Impact factor: 4.176

6.  Heterotopic ossification rates after acetabular fracture surgery are unchanged without indomethacin prophylaxis.

Authors:  Sean M Griffin; Stephen H Sims; Madhav A Karunakar; Rachel Seymour; Nikkole Haines
Journal:  Clin Orthop Relat Res       Date:  2013-09       Impact factor: 4.176

7.  Minimal-invasive posterior approach in the treatment of the posterior wall fractures of the acetabulum.

Authors:  Rosario Spagnolo; Matteo Bonalumi; Fabrizio Pace; Dario Capitani
Journal:  Chir Organi Mov       Date:  2009-04-28

8.  Results of operative treatment of acetabular fractures from the Third World--how local factors affect the outcome.

Authors:  Ravi K Gupta; Harmeet Singh; Bias Dev; Rajeev Kansay; Parmanand Gupta; Sudhir Garg
Journal:  Int Orthop       Date:  2007-10-17       Impact factor: 3.075

9.  An anatomic classification for heterotopic ossification about the hip.

Authors:  Malcolm R DeBaun; Chason Ziino; Christopher LaPrade; Stephanie Pun; Raffi S Avedian; Michael J Bellino
Journal:  J Orthop       Date:  2020-03-28

Review 10.  Is radiation superior to indomethacin to prevent heterotopic ossification in acetabular fractures?: a systematic review.

Authors:  Taco J Blokhuis; Jan Paul M Frölke
Journal:  Clin Orthop Relat Res       Date:  2008-09-27       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.